WOBE437
WOBE437 is a selective endocannabinoid reuptake inhibitor (SERI) which has been used in scientific research.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
WOBE437 is a selective endocannabinoid reuptake inhibitor (SERI) which has been used in scientific research. It is a highly potent and selective endocannabinoid reuptake inhibitor, with an of 10 nM in terms of this action. The drug produces anxiolytic-like, anti-inflammatory, analgesic, antiallodynic, and muscle relaxant effects in rodents.
These effects are mediated by increased endocannabinoid levels, including of anandamide (AEA) and 2-arachidonylglycerol (2-AG), and are dependent on cannabinoid receptors, for instance the cannabinoid CB 1 receptor. Conversely, WOBE437 did not produce catalepsy, affect locomotor activity, or produce the typical sedation of cannabinoid CB 1 receptor agonists.
The drug also showed effectiveness in an animal model of multiple sclerosis. Originally believed to be selective, off-target activities of WOBE437 have subsequently been identified and described. WOBE437 is orally bioavailable in rodents.
Numerous analogues of WOBE437 have been explored in search of candidates with better drug-like properties, though a series of almost 80 compounds found none that were more potent than WOBE437 itself. WOBE437 was first described in the scientific literature by 2013.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1359009967 under CC BY-SA 4.0; modifications have been made.